Diabetic retinopathy is associated with diastolic dysfunction in type 2 diabetic patients with non-ischemic dilated cardiomyopathy.
Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
Impact of Alpha Lipoic Acid as an Adjuvant Therapy on Inflammation and Fibrosis in Type 2 Diabetic Patients with Ischemic Cardiomyopathy: A Randomized Controlled Trial.
Oxidative stress and diabetic complications.
Giacco F, Brownlee M.
Circ Res. 2010 Oct 29;107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545.
Endothelial Dysfunction and Diabetic Cardiomyopathy.
Wang M, Li Y, Li S, Lv J.
Front Endocrinol (Lausanne). 2022 Apr 7;13:851941. doi: 10.3389/fendo.2022.851941. eCollection 2022.
Molecular mechanisms of diabetic cardiomyopathy.
Bugger H, Abel ED.
Diabetologia. 2014 Apr;57(4):660-71. doi: 10.1007/s00125-014-3171-6. Epub 2014 Jan 30.
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes.
Park JJ.
Diabetes Metab J. 2021 Mar;45(2):146-157. doi: 10.4093/dmj.2020.0282. Epub 2021 Mar 25.
Mechanism of Ferroptosis and Its Role in Type 2 Diabetes Mellitus.
Sha W, Hu F, Xi Y, Chu Y, Bu S.
J Diabetes Res. 2021 Jun 28;2021:9999612. doi: 10.1155/2021/9999612. eCollection 2021.
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging.
Ng ACT, Delgado V, Borlaug BA, Bax JJ.
Nat Rev Cardiol. 2021 Apr;18(4):291-304. doi: 10.1038/s41569-020-00465-5. Epub 2020 Nov 13.
Diabetic Cardiomyopathy: Does the Type of Diabetes Matter?
Hölscher ME, Bode C, Bugger H.
Int J Mol Sci. 2016 Dec 18;17(12):2136. doi: 10.3390/ijms17122136.
Targeting immunometabolic pathways with AZD1656 alleviates inflammation and metabolic dysfunction in type 2 diabetic cardiomyopathy.
Anderson S, Karlstaedt A, Young M, Karatzia L, Cullen F, Chen J, O'Riordan CE, Barnes MR, Štaka Z, Albee LJ, Garrod-Ketchley C, Dambure S, Prag HA, Cvetko F, Miller JJJJ, Thiemermann C, Lewis AJM, Murphy MP, Smith DM, Henson SM, Tyler DJ, Aksentijevic D.
Nat Cardiovasc Res. 2026 Feb;5(2):138-154. doi: 10.1038/s44161-025-00769-0. Epub 2026 Feb 23.
Lipotoxicity in type 2 diabetic cardiomyopathy.
van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P.
Cardiovasc Res. 2011 Oct 1;92(1):10-8. doi: 10.1093/cvr/cvr212. Epub 2011 Jul 29.
ZIP7 contributes to the pathogenesis of diabetic cardiomyopathy by suppressing mitophagy in mouse hearts.
Yang N, Zhang R, Zhang H, Yu Y, Xu Z.
Cardiovasc Diabetol. 2024 Nov 7;23(1):399. doi: 10.1186/s12933-024-02499-2.
